

National Institute for Health and Care Excellence

Health Technology Evaluation

**Talazoparib for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations [ID1342]
Response to stakeholder organisation comments on the draft remit and draft scope**

Please note: Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

Comment 1: the draft remit and proposed process

Section	Stakeholder	Comments [sic]	Action
Appropriateness	Pfizer	This topic is appropriate for a NICE appraisal.	Thank you for your comment. No action required.
Wording	Pfizer	Yes, the wording of the scope is appropriate.	Thank you for your comment. No action required.
Timing Issues	Pfizer	N/a	-

Comment 2: the draft scope

Section	Consultee/ Commentator	Comments [sic]	Action
Background information	Pfizer	The background information is accurate and complete.	Thank you for your comment. No action required.
The technology/ intervention	Pfizer	Yes	Thank you for your comment. No action required.
Population	Pfizer	Yes	Thank you for your comment. No action required.
Comparators	Pfizer	Carboplatin may also be considered a relevant comparator for BRCA1/2-mutated and triple-negative breast cancer. Tutt, Andrew, et al. "Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial." <i>Nature medicine</i> 24.5 (2018): 628-637.	Thank you for your comments. Carboplatin is not recommended for use in locally advanced or metastatic breast cancer. No action required.
Outcomes	Pfizer	Yes	Thank you for your comment. No action required.
Economic analysis	Pfizer	The economic analysis is appropriate.	Thank you for your comment. No action required.

Section	Consultee/ Commentator	Comments [sic]	Action
Equality	Pfizer	There are no anticipated equality issues.	Thank you for your comment. No action required.
Other considerations	Pfizer	N/a	-
Innovation	Pfizer	N/a	-
Questions for consultation	Pfizer	N/a	-

The following stakeholders indicated that they had no comments on the draft remit and/or the draft scope

None.